The news that Moderna’s (NSDQ:MRNA) COVID-19 had a small risk of facial swelling for patients with dermal fillers has spooked scores of patients. Dermatologists and plastic surgeons have been inundated with queries from concerned patients. But the risk of problems is miniscule, according to Dr. Wilbur Hah, the president of the American Board of Cosmetic Surgery (ABCS).
In the following interview, Dr. Hah puts the risk into perspective, explains why Botox recipients are unlikely to experience vaccine-induced facial swelling and provides a suggestion for drug developers and the CDC.
1. How would you characterize the reaction from patients concerned about Moderna’s vaccine reactivity to dermal fillers?
Hah: Though it is a potential risk, I want to emphasi…